Skip to main content
. 2023 Feb 16;12(2):687–700. doi: 10.1007/s40120-023-00448-x

Fig. 1.

Fig. 1

Study design. aIncluding dimethyl fumarate and diroximel fumarate. bAny interferon and peginterferon beta-1a. cMeasured using sCOVg, Siemens Healthineers. dMeasured using T cell receptor sequencing (ImmunoSEQ T-MAP COVID). Anti-RBD IgG SARS-CoV-2 spike receptor binding domain, DMT disease-modifying therapy, MS multiple sclerosis